The thickness of corneal pachymetry and the epithelium after accelerated (45 mW/cm 2 ) transepithelial corneal collagen cross-linking (CXL) for keratoconus were assessed in this prospective case series study. Twenty-eight patients were treated for keratoconus. The mean Kmax was 56.18 ± 7.90. The thinnest point, as assessed by optical coherence tomography (OCT), was 443.18 ± 39.75 μm. Accelerated transepithelial CXL was performed, and corrected distance visual acuity (CDVA), corneal topography, and OCT were recorded at 1 week postoperatively as well as at 1, 3, 6, and 12 months. The surgery was uneventful in all eyes. Postoperative epithelial edema was observed and faded in 3 days. The postoperative Kmax was 54.56 ± 8.81, 55.78 ± 8.11, 56.37 ± 8.71, 55.80 ± 7.92, and 55.47 ± 8.24 at 1 week, 1 month, 3 months, 6 months, and 12 months, respectively (all, P > 0.05). The thinnest postoperative corneal point, 439.04 ± 44.99 μm, was observed at 12 months (P = 0.109). The epithelial thickness decreased during the first postoperative week then showed a gradual recovery. Postoperative pachymetry thickness showed no significant changes for up to 12 months. Postoperative epithelial thickness decreased temporarily, then stabilized at month 12. Accelerated transepithelial CXL was shown to be effective and safe for the treatment of keratoconus.Keratoconus (KC) is a degenerative, bilateral, asymmetrical, non-inflammatory disease that induces biomechanical corneal weakening due to aberrant changes in organization and the structure of stromal corneal collagen fibers 1,2 , which is a serious ocular disorder that can cause severe loss of vision 3 . The recommended treatment is deep anterior lamellar keratoplasty or a penetrating corneal graft for patients in advanced stages that have contact lens intolerance and/or dense stromal scars 4 . Corneal collagen cross-linking (CXL) is used to treat keratoconus and keratectasia by strengthening corneal tissue through an interaction using a riboflavin photosensitizer and ultraviolet (UV) light. This treatment is based on an increase in covalent bonds within or between corneal collagen molecules that increases the biomechanical strength of the cornea 5,6 . This traditional protocol requires debridement of the corneal epithelium to promote diffusion of riboflavin into the corneal stroma 7 . Postoperative pain, infection, and even stromal haze are caused by the complex structural and physiological wound healing changes after CXL 4,8 . Long-term clinical studies showed the result of slowing, and in most cases blocking, keratoconus progression as well as improving refractive and topographic features [9][10][11][12] . Accelerated transepithelial or "epithelium-on" CXL is a technique performed without epithelial debridement by applying topical drugs to loosen the tight junctions of the corneal epithelial cells to facilitate riboflavin penetration through an intact epithelium. This technique was proposed to reduce the risk of complications caused by epithelial removal, such as postoperative pain an...